Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma

Cancer Gene Therapy volume 19, pages 101–109 (2012)Cite this article

Abstract

Vesicular stomatitis virus (VSV) matrix protein (MP) can induce in vitro apoptosis of tumor cells in the absence of other viral components. Here, the antitumor activity of VSV-MP against lung adenocarcinoma was investigated in vivo. A pVAX-plasmid DNA encoding VSV-MP and control empty vectors (pVAX) were constructed and wrapped-up with liposome. A549 and Spc-A1 human lung adenocarcinoma cells were transfected with liposomal-VSV-MP (Lip-MP) or Lip-pVAX and then examined for cell viability or apoptosis using Hoechst/propidium iodide staining by flow cytometry, and further demonstrated by caspase/poly ADP-ribose polymerase (PARP) cleavage analysis. For the in vivo study, A549 and Spc-A1 lung carcinoma models in nude mice were established and randomly assigned into three groups to receive eight 2-weekly intravenous administrations of medium alone as control, Lip-pVAX or Lip-MP, respectively. Subsequently, Lip-MP significantly reduced tumor growth and prolonged the survival of tumor-bearing mice compared with Lip-pVAX and control agents (P<0.05), with much higher apoptosis index of both in vivo and in vitro tumor cells, respectively (P<0.05). In addition, in vivo antitumoral effect was associated with natural killer-(NK) cell congregation without evidence of toxicity. These observations suggest that systemically delivering Lip-MP has a specific dual antitumor activity in human lung adenocarcinoma by inducing apoptosis and possibly stimulating NK-cell responses, it may provide a clue for developing new therapeutic approaches against human lung adenocarcinoma.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4
Figure 5
Figure 6

Similar content being viewed by others

References

  1. Peacock CD, Watkins DN . Cancer stem cells and the ontogeny of lung cancer. J Clin Oncol 2008; 26: 2883–2889.

    Article  CAS  PubMed  Google Scholar 

  2. Navada S, Lai P, Schwartz AG, Oton AB, Gooding WE, Taioli E . Temporal trends in small cell lung cancer: analysis of the national Surveillance Epidemiology and End-Results (SEER) database [abstract 7082]. J Clin Oncol 2006; 24 (Suppl): 384S.

    Google Scholar 

  3. Sher T, Dy GK, Adjei AA . Small cell lung cancer. Mayo Clin Proc 2008; 83: 355–367.

    Article  CAS  PubMed  Google Scholar 

  4. Franceschi S, Bidoli E . The epidemiology of lung cancer. Ann Oncol 1999; 10 (Suppl 5): S3–S6.

    Article  PubMed  Google Scholar 

  5. Koyama AH . Induction of apoptotic DNA fragmentation by the infection of vesicular stomatitis virus. Virus Res 1995; 37: 285–290.

    Article  CAS  PubMed  Google Scholar 

  6. Balachandran S, Barber GN . Defective translational control facilitates vesicular stomatitis virus oncolysis. Cancer Cell 2004; 5: 51–65.

    Article  CAS  PubMed  Google Scholar 

  7. Stojdl DF, Lichty B, Knowles S, Marius R, Atkins H, Sonenberg N . Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000; 6: 821–825.

    Article  CAS  PubMed  Google Scholar 

  8. Fernandez M, Porosnicu M, Markovic D, Barber GN . Genetically engineered vesicular stomatitis virus in gene therapy: application for treatment of malignant disease. J Virol 2002; 76: 895–904.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Ebert O, Shinozaki K, Huang TG, Savontaus MJ, García-Sastre A, Woo SL . Oncolytic vesicular stomatitis virus for treatment of orthotopic hepatocellular carcinoma in immune-competent rats. Cancer Res 2003; 63: 3605–3611.

    CAS  PubMed  Google Scholar 

  10. Shinozaki K, Ebert O . Koumioti C Oncolysis of multifocal hepatocellular carcinoma in the rat liver by hepatic artery infusion of vesicular stomatitis virus. Mol Ther 2004; 9: 368–376.

    Article  CAS  PubMed  Google Scholar 

  11. Li Q, Wei YQ, Wen YJ, Zhao X, Tian L, Yang L . Induction of apoptosis and tumor regression by vesicular stomatitis virus in the presence of gemcitabine in lung cancer. Int J Cancer 2004; 112: 143–149.

    Article  CAS  PubMed  Google Scholar 

  12. Ahmed M, Cramer SD, Lyles DS . Sensitivity of prostate tumors to wild type and M protein mutant vesicular stomatitis viruses. Virol 2004; 330: 34–49.

    Article  CAS  Google Scholar 

  13. Ebert O, Harbaran S, Shinozaki K, Woo SL . Systemic therapy of experimental breast cancer metastases by mutant vesicular stomatitis virus in immune-competent mice. Cancer Gen Ther 2005; 12: 350–358.

    Article  CAS  Google Scholar 

  14. Letchworth GJ, Rodriguez LL, Del CBJ . Vesicular stomatitis. Vet J 1999; 157: 239–260.

    Article  CAS  PubMed  Google Scholar 

  15. Black BL, Lyles DS . Vesicular stomatitis virus matrix protein inhibits host cell-directed transcription of target genes in vivo. J Virol 1992; 66: 4058–4064.

    CAS  PubMed  PubMed Central  Google Scholar 

  16. Black BL, Rhodes RB, McKenzie M, Lyles DS . The role of vesicular stomatitis virus matrix protein in inhibition of hostdirected gene expression is genetically separable from its function in virus assembly. J Virol 1993; 67: 4814–4821.

    CAS  PubMed  PubMed Central  Google Scholar 

  17. Paik SY, Banerjea AC, Harmison GG, Chen CJ, Schubert M . Inducible and conditional inhibition of human immunodeficiency virus proviral expression by vesicular stomatitis matrix protein. J Virol 1995; 69: 3529–3537.

    CAS  PubMed  PubMed Central  Google Scholar 

  18. Ferran MC, Lucas-Lenard JM . The vesicular stomatitis virus matrix protein inhibits transcription from the human beta interferon promoter. J Virol 1997; 71: 371–377.

    CAS  PubMed  PubMed Central  Google Scholar 

  19. Ahmed M, Lyles DS . Effect of vesicular stomatitis virus matrix protein on transcription directed by host RNA II polymerasesI, and III. J Virol 1998; 72: 8413–8419.

    CAS  PubMed  PubMed Central  Google Scholar 

  20. Yuan H, Yoza BK, Lyles DS . Inhibition of host RNA polymerase II-dependent transcription by vesicular stomatitis virus results from inactivation of TFIID. Virology 1998; 251: 83–92.

    Article  Google Scholar 

  21. Yuan H, Puckett S, Lyles DS . Inhibition of host transcription by vesicular stomatitis virus involves a novel mechanism that is independent of phosphorylation of TATA-Binding protein (TBP) or association of TBP with TBP-associated factor subunits. J Virol 2001; 75: 4453–4458.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Ahmed M, McKenzie MO, Puckett S . Ability of the matrix protein of vesicular stomatitis virus to suppress beta interferon gene expression is genetically correlated with the inhibition of host RNA and protein synthesis. J Virol 2003; 77: 4646–4657.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Her LS, Lund E, Dahlberg JE . Inhibition of Ran guanosine triphosphatase dependent nuclear transport by the matrix protein of vesicular stomatitis virus. Science 1997; 276: 1845–1848.

    Article  CAS  PubMed  Google Scholar 

  24. Petersen JM, Her LS, Varvel V . The matrix protein of vesicular stomatitis virus inhibits nucleocytoplasmic transport when it is in the nucleus and associated with nuclear pore complexes. Mol Cell Biol 2000; 20: 8590–8601.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Kobbe CV, Deursen JMV, Rodrigues JP, Sitterlin D, Bachi A, Wu X et al. Vesicular stomatitis virus matrix protein inhibits host cell gene expression by targeting the nucleoporin Nup98. Mol Cell 2000; 6: 1243–1252.

    Article  Google Scholar 

  26. Blondel D, Harmison GG, Schubert M . Role of matrix protein in cytopathogenesis of vesicular stomatitis virus. J Virol 1990; 64: 1716–1725.

    CAS  PubMed  PubMed Central  Google Scholar 

  27. Melki R, Gaudin Y, Blondel D . Interaction between tubulin and the viral matrix protein of vesicular stomatitis virus: possible implications in the viral cytopathic effect. Virology 1994; 202: 339–347.

    Article  CAS  PubMed  Google Scholar 

  28. Lin X, Chen X, Wei Y, Zhao J, Fan L, Wen Y et al. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice. Gynecol Oncol 2007; 104: 540–546.

    Article  CAS  PubMed  Google Scholar 

  29. Zhong Q, Wen YJ, Yang HS, Luo H, Fu AF, Yang F et al. Efficient inhibition of cisplatin-resistant human ovarian cancer growth and prolonged survival by gene transferred vesicular stomatitis virus matrix protein in nude mice. Ann Oncol 2008; 19: 1584–1591.

    Article  CAS  PubMed  Google Scholar 

  30. Shi W, Tang Q, Chen X, Cheng P, Jiang P, Jing X et al. Antitumor and antimetastatic activities of vesicular stomatitis virus matrix protein in a murine model of breast cancer. J Mol Med 2009; 87: 493–506.

    Article  CAS  PubMed  Google Scholar 

  31. Bell JC, Lichty B, Stojdl D . Getting oncolytic virus therapies off the ground. Cancer Cell 2003; 4: 7–11.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

This work was supported by National 973 Project (No. 2010CB529900) and National Natural Science Foundation (No. 30973452).

Author contributions: Xiaomei Jing, Wei Shi, Qingqing Tang contributed to the experimental work, data analysis and manuscript writing; Yanjun Wen and Jiong Li contributed to the construction of expression vector and preparation of liposome; Xiancheng Chen was engaged in devising the project and revising the manuscript.

Author information

Authors and Affiliations

  1. State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, People's Republic of China

    X-M Jing, Y-J Wen, Q-Q Tang, J Li & X-C Chen

  2. Department of Chemotherapy, Sichuan Cancer Hospital, Chengdu, Sichuan, People's Republic of China

    X-M Jing & W Shi

Authors
  1. X-M Jing
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Y-J Wen
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. W Shi
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Q-Q Tang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. J Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. X-C Chen
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to X-C Chen.

Ethics declarations

Competing interests

The authors declare no conflict of interest.

Additional information

Supplementary Information accompanies the paper on Cancer Gene Therapy website

Supplementary information

Rights and permissions

Reprints and permissions

About this article

Cite this article

Jing, XM., Wen, YJ., Shi, W. et al. VSV-MP gene therapy strategy inhibits tumor growth in nude mice model of human lung adenocarcinoma. Cancer Gene Ther 19, 101–109 (2012). https://doi.org/10.1038/cgt.2011.71

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/cgt.2011.71

Keywords

This article is cited by

Search

Advanced search

Quick links